Bank of America Global Healthcare Conference 2026
Logotype for Cardinal Health Inc

Cardinal Health (CAH) Bank of America Global Healthcare Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Cardinal Health Inc

Bank of America Global Healthcare Conference 2026 summary

8 Jul, 2026

Financial performance and guidance

  • Delivered strong Q3 results with 18% profit growth in pharma and over 30% profit growth in three other growth businesses.

  • Raised non-GAAP EPS guidance to $10.70-$10.80, reflecting operational performance and strong demand across the portfolio.

  • Specialty business grew over 20% in the quarter and year-to-date, with continued momentum expected into Q4 and next year.

  • Adjusted free cash flow guidance increased to $3.3-$3.7 billion for the year, supported by resilient business model and disciplined capital allocation.

  • Share repurchases exceeded $1 billion year-to-date, surpassing the initial $750 million commitment.

Strategic investments and M&A

  • Continued execution on MSO integration, including closing Solaris and ongoing tuck-in acquisitions in GI and urology platforms.

  • Acquired leading platforms in gastroenterology (GI Alliance) and urology (Urology America, Solaris), focusing on building an ecosystem around community practitioners.

  • Investments in technology, process, and team aim to make the company the partner of choice for fragmented specialties.

  • Diversification of revenue streams through MSOs in urology, gastroenterology, and oncology, with ongoing opportunities for cross-business synergies.

Business segment highlights

  • Specialty and biopharma services, including Sonexus, are on track to double supported therapies by fiscal 2028, driven by new customer wins and investments in technology.

  • GMPD business benefits from contractual protections against commodity volatility and focuses on innovation and private label growth, especially in acute and ASC environments.

  • Cardinal Health Brand grew 5% in Q3, with continued focus on innovation and expanding private label offerings.

  • Nuclear and Precision Health Solutions maintains a leading market position, with over 70 products in the pipeline and $150 million invested in PET network expansion.

  • OptiFreight Logistics continues to take market share, providing significant customer savings and strong growth despite being the smallest reporting unit.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more